WHO ICTRP trial
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour…
CTIS2022-502703-30-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2022-502703-30-00 |
|---|---|
| Public title | Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) |
| Scientific title | Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) - SAUNA |
| Primary sponsor | Antwerp University Hospital |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use - (Phase IV): yes |
| Countries | Belgium |
| Conditions | neuroendocrine tumours MedDRA version: 20.0Level: PTClassification code: 10077559Term: Gastroenteropancreatic neuroendocrine tumour diseaseSystem Organ Class: 100000004864 MedDRA version: 21.0Level: PTClassification code: 10052399Term… |
| Interventions | Product Name: LANREOTIDE,Product Code: SUB08402MIG,Pharmaceutical Form: SOLUTION FOR INJECTION,Other descriptive name: ,Strength: 120mg,Product Name: SUNITINIB,Product Code: SUB22321,Pharmaceutical Form: CAPSULE, HARD,Other descriptive… |
| Registration date | Feb 28, 2023 |
| Target size | 135 |
| Secondary IDs | NCT05701241 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: